AYTU BIOPHARMA, INC Other Asset Impairment Charges
AYTU BIOPHARMA, INC (AYTU) reported Other Asset Impairment Charges of $5.71 million for the 12-month period ending 2023-06-30, per its 10-K filed 2023-10-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherAssetImpairmentCharges · last filed 2023-10-12
- AYTU BIOPHARMA, INC other asset impairment charges for fiscal 2023 was $5.71M, a 40.92% decline from fiscal 2022.
- AYTU BIOPHARMA, INC other asset impairment charges for fiscal 2022 was $9.66M.
| Period end | Other Asset Impairment Charges 12 month |
|---|---|
| 2023-06-30 | $5.71M 10-K · filed 2023-10-12 |
| 2022-06-30 | $9.66M 10-K · filed 2023-10-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |